Posted by Gary Schwitzer in Health care journalism
This may be a trend. And if so, it’s a troubling one.
On HealthNewsReview.org, we’ve just posted a review of a Wall Street Journal story that we characterize as
“Another story that lets a drug company get away with making superiority claims without releasing data.”
Many news orgs let the makers of Provenge get away with this just a few days ago.
Stock manipulation anyone?
Is it going to kill anyone to wait until the data is actually released when independent expert opinion can be sought?
We don’t like this practice one bit.
Read how the the European Court of Justice views journalism that it equates with advertising.
At least on the Chicago Tribune’s website, this story appeared in the Health section – not the local business or feature section. It didn’t address most of the things we think are crucial in a health story.
“Brown fat” has ignited a grease fire of media hype in recent weeks.This WebMD story missed a good opportunity to smother the flames.
We reviewed this story and a competing AP story on these new fibroid studies. Read and compare.
We will not display your name or e-mail address on the site, nor will we share youre-mail address with any third parties.
For site updates and news from Gary, find us on Twitter:
HealthNewsReview: @HealthNewsRevu
Gary Schwitzer: @garyschwitzer
Copyright © 2012 Health News Review
Add Comment
Disclaimer: I welcome comments but will delete those with any kind of product pitch, profanity, personal attacks or those from anyone who doesn’t list what appears to be an actual e-mail address. I will also end any thread of comments that are repetitive. Because I moderate comments, I can’t keep reacting to repeatedly inaccurate or unsubstantiated claims. We don't give medical advice so we won't respond to questions asking for it.